Company Description
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.
It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide.
The company was incorporated in 2009 and is based in Jerusalem, Israel.
| Country | Israel |
| Founded | 2010 |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Miranda Toledano |
Contact Details
Address: Kiryat Hadassah Minrav Building, 5th Floor Jerusalem, 9112002 Israel | |
| Phone | 972 2 532 7151 |
| Website | enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer and Director |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Gregory Burshtein Ph.D. | Chief of Research and Development |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Rachel B. Wagman | Chief Clinical Advisor |
| Cherin Smith | Executive Vice President and Head of Clinical Operations |
| Dr. Constantin Itin Ph.D., R.Ph. | Head of Biopharmaceutics and Bioanalytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | EFFECT | Notice of Effectiveness |
| May 15, 2026 | 424B3 | Prospectus |
| May 14, 2026 | PRE 14A | Other preliminary proxy statements |
| May 8, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2026 | 10-Q | Quarterly Report |
| May 8, 2026 | 8-K | Current Report |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 10-K | Annual Report |
| Mar 27, 2026 | 8-K | Current Report |
| Mar 4, 2026 | 8-K | Current Report |